Johnson & Johnson (JNJ)vsPhreesia Inc (PHR)
JNJ
Johnson & Johnson
$224.26
+1.28%
HEALTHCARE · Cap: $535.63B
PHR
Phreesia Inc
$9.57
-5.90%
HEALTHCARE · Cap: $581.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 19951% more annual revenue ($96.36B vs $480.59M). JNJ leads profitability with a 21.8% profit margin vs 0.5%. JNJ trades at a lower P/E of 25.8x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
PHR
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$160.99
Current Price
$224.26
$63.27 premium
Margin of Safety
+77.8%
Fair Value
$56.21
Current Price
$9.57
$46.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
15.9% revenue growth
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.8% — below average capital efficiency
0.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : PHR
The strongest argument for PHR centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 239.3x leaves little room for execution misses. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PHR is a growth play — different risk/reward profiles.
PHR carries more volatility with a beta of 0.89 — expect wider price swings.
PHR is growing revenue faster at 15.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 43/100), backed by strong 21.8% margins. PHR offers better value entry with a 77.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?